The role of soluble guanylate cyclase stimulator riociguat in preventing the development of reperfusion lung injury after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension

Aim. To evaluate the effect of prior administration of the soluble guanylate cyclase stimulator riociguat on the incidence and severity of reperfusion lung injury after balloon pulmonary angioplasty (BPA) in patients with inoperable form of chronic thromboembolic pulmonary hypertension (CTEPH).

Materials and methods. 70 patients with inoperable CTEPH were included in the study. Patients were divided into 2 groups: Group 1 (n=41) – patients who had received PAH-specific therapy with riociguat at the time of BPA, Group 2 (n=29) – patients who underwent BPA without prior administration of riociguat. In the postoperative period all the patients underwent noninvasive artificial ventilation in continuous positive airway pressure mode in order to prevent the development of reperfusion damage of lungs.

Results. Patients of group 1 received treatment with riocigiat for 6 months. At the time of BPA patients of both groups were matched for hemodynamic characteristics. In group 1, reperfusion edema above grade 1 occurred in 17.1% of patients, in group 2 – in 20.7% of patients, p=0.702. In group 1, manifestations of grade 3 reperfusion edema were found in 9.8% patients vs. 6.9% patients in group 2, (p=0.638). None of the patients in both groups had grade 4 or 5 reperfusion edema. Values of the index predicting the probability of reperfusion injury (PEPSI) were not significantly different in the group of patients who were pretreated with riociguat and in the group of patients who did not get PAH-specific therapy (p=0,588).

Conclusion. There was no reliable evidence that administration of riociguat in recommended doses at least 6 months before BPA results in additional reduction in the incidence and severity of reperfusion pulmonary edema in patients with inoperable CTEPH.

1. Chazova I.E., Martynyuk T.V., Valieva Z.S. et al. Eurasian Association Of Cardiology (EAC) guidelines for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (2020). Eurasian heart journal. 2021;(1):6-43. (In Russ.). https://doi.org/10.38109/22251685-2021-1-6-43

2. Humbert M., Kovacs G., Hoeper M. et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Eur Heart J. 2022;43(7):67-119. https://doi.org/10.1093/eurheartj/ehac237

3. Ghofrani HA, D’Armini AM, Grimminger F et al. CHEST-1 Study Group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369 (4):319-329. https://doi.org/10.1056/NEJMoa1209657

4. Simonneau G, D’Armini AM, Ghofrani HA et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J. 2015;45(5):1293-302. https://doi.org/10.1183/09031936.00087114

5. Jaïs X, Brenot P, Bouvaist H et al. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, openlabel, randomised controlled trial and ancillary follow-up study.The Lancet Respiratory Medicine. 2022;10(10):961-971. https://doi.org/10.1016/S2213-2600(22)00214-4

6. Mahmud E, Patel M, Ang L, Poch D. et al. Advances in balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Pulm Circ. 2021 May 24;11(2):20458940211007385. PMID: 34104421; PMCID: PMC8150503. https://doi.org/10.1177/20458940211007385

7. Lang IM, Andreassen AK, Andersen A et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a clinical consensus statement of the ESC working group on pulmonary circulation and right ventricular function. Eur Heart J. 2023;44(29):2659-2671. https://doi.org/10.1093/eurheartj/ehad413

8. Inami T, Kataoka M, Shimura N et al. Pulmonary edema predictive scoring index (PEPSI), a new index to predict risk of reperfusion pulmonary edema and improvement of hemodynamics in percutaneous transluminal pulmonary angioplasty. JACC Cardiovasc Interv. 2013; (6): 725-736. https://doi.org/10.1016/j.jcin.2013.03.009

9. Ueda J, Ogo T, Asano R et al. Riociguat as a bridge therapy for balloon pulmonary angioplasty in patients with severe chronic thromboembolic pulmonary hypertension. European Heart Journal. 2017;(38):2597. https://doi.org/10.1093/eurheartj/ehx502.P2597

10. Kawakami T, Matsubara H, Shinke T et al. Balloon pulmonary angioplasty versus riociguat in inoperable chronic thromboembolic pulmonary hypertension (MR BPA): an open-label, randomised controlled trial. The Lancet Respiratory Medicine.2022;10(10):949-960. https://doi.org/10.1016/S2213-2600(22)00171-0

11. Jain N, Sheikh M, Bajaj D et al. Periprocedural Complications With Balloon Pulmonary Angioplasty: Analysis of Global Studies. J Am Coll Cardiol Intv. 2023;16 (8):976-983. https://doi.org/10.1016/j.jcin.2023.01.361

12. Elfimova E.M., Danilov N.M., Yarovoy S.Yu., Mikhailova O.O., Litvin A.Yu., Matchin Yu.G., Chazova I.E. Effect of CPAP therapy on the reperfusion lung injury after transluminal balloon angioplasty of the pulmonary arteries in patients with chronic thromboembolic pulmonary hypertension. Systemic Hypertension. 2023;20(3):11-18. (In Russ.). https://doi.org/10.38109/2075-082X-2023-3-11-18

13. Danilov N.M., Yarovoy S.Yu., Elfimova E.M., Mikhailova O.O., Litvin A.Yu., Danilushkin Yu.V., Matchin Yu.G., Chazova I.E. Clinical and radiological aspects of reperfusion pulmonary edema after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Systemic Hypertension. 2022;19(3):23-30. (In Russ.). https://doi.org/10.38109/2075-082X-2022-3-23-30

14. Wiedenroth CB, Ghofrani HA, Miriam SD, et al. Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. Pulmonary Circulation. 2018;8(3):2045894018783996. https://doi.org/10.1177/2045894018783996